| Akari Therapeutics Plc |
Director, 10%+ Owner |
American Depositary Shares representing Ordinary Shares |
3,031,005 |
$3,394,726 |
$1.12 |
20 Mar 2025 |
PranaBio Investments LLC |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Ordinary Shares, par value $0.0001 per share |
5,249,511,500 |
$3,149,707 |
$0.000600 |
03 Jan 2025 |
PranaBio Investments LLC |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Series A Warrants (Right to Buy) |
406,250 |
$455,000 |
$1.12 |
06 Mar 2025 |
PranaBio Investments LLC |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Series B Warrants (Right to Buy) |
406,250 |
$455,000 |
$1.12 |
06 Mar 2025 |
PranaBio Investments LLC |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Pre-Funded Warrants to purchase ADRs |
618,658 |
$249,999 |
$0.4041 |
16 Dec 2025 |
Direct |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Pre-Funded Warrants to purchase ADRs |
231,997 |
$93,749 |
$0.4041 |
16 Dec 2025 |
PranaBio Investments LLC |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Ordinary Shares, par value $0.0001 per share |
91,396,000 |
$54,838 |
$0.000600 |
03 Jan 2025 |
Direct |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
American Depositary Shares representing Ordinary Shares |
45,698 |
$51,182 |
$1.12 |
20 Mar 2025 |
Direct |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Warrants to purchase American Depositary Shares ("ADRs") |
618,658 |
|
|
16 Dec 2025 |
Direct |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Warrants to purchase ADRs |
231,997 |
|
|
16 Dec 2025 |
PranaBio Investments LLC |
| Akari Therapeutics Plc |
Director, 10%+ Owner |
Stock Option (Right to Buy) |
225,000 |
|
|
20 Mar 2025 |
Direct |
| CytoDyn Inc. |
Director |
Non-qualified Stock Option |
12,329 |
|
|
24 Nov 2021 |
Direct |